DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
DISTRICT OFFICE ADDRESS AND PHONE NUMBER	DATE(S) OF INSE	DATE(S) OF INSPECTION		
4040 N. Central Expressway, #300 Dallas, TX 75204	11/28/17-12/	2		
214-253-5200	FEI NUMBER			
Industry Information: www.fda.gov/oc/industry	3005331940	e g		
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED				
TO: Kimberly J. Fontenot, Pharmacist-in-Charge				
IRM NAME STREET ADDRESS				
Peoples Pharmacy, Inc.	3801-B S. Lamar Blvd.			
CITY, STATE AND ZIP CODE	TYPE OF ESTABLISHMENT INSPECTED			
Austin, TX 78704	Producer of Non-Sterile Drugs			
THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE. DURING AN INSPECTION OF YOUR FIRM (I) (WE) OBSERVED:				
OBSERVATION I				
Non-pharmaceutical grade components are used in the formulation of non-sterile drug products. For example,				
a) Your firm uses water from a (b) (4)	system for use in certain drug prod	lucts whose formulation		
requires water. Your firm is also using the water from	- This is the first of the first of the contract of the contra	The second difference of the contract of the c		
(b) (4)) for use in certain drug products. Your firm	물리 그렇게 맛있다니 뭐하게 그 때 없다면 얼굴할 때 맛이 있을 할 때 있다. 그는 맛이 맛있다니다 하다 그를 먹고 있다고 있다.	50-17-0-2007-00-00-00-00-00-00-00-00-00-00-00-00-		
(microbiological or analytical) to show the water at lea				
USP. Examples of lots made using the (b) (4) water inclu				
Free) 0.05mg/lmL Suspension and lot #11-13-2017@	of Omeprazole (Grape/Marshma	llow) Standard + 2mg/mL		
Suspension. Examples of products made using the (b) #11-12-2017@12 of Dexamethasone/Mupirocin/Ampl	(4) Water made from the	water include for		
Spray and lot #06-15-2017@21 of Tranexamic Acid 5		B) I Amb, DAUTE INSPRI		
apray and lot #00-13-201/16021 of Franchamic Acid 5	70 Solution.	Ä		
b) Your firm uses Acetone CP grade for making drug	products. The Acetone is labeled	for "technical use only".		
In the past 6 months your firm has made ots of drug	products using Acetone CP include	ding (b) (4);		
(b) (4) of Squaric Acid Dibutyl Ester/Acetone 0.5% Solution and (b) (4);				
(b) (4) of Diphenylcycl	opropenone 5% Solution.			
OBSERVATION 2				
Hazardous or highly potent drugs were produced without providing adequate containment, segregation and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.				
or work surfaces, dictions, and or personner to prevent cross-containing our				
EMPLOYEE(S) SIGNATURE	EMPLOYEE(\$) NAME AND TITLE (Print or Type)	DATE ISSUED		
SEE REVERSE OF THIS PAGE Margaret M. Guney	Margaret M. Annes, CSO	12/07/2017		

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
- CONTROL OFFICE				
DISTRICT OFFICE ADDRESS AND PHONE NUMBER			OF INSPECTION	
	al Expressway, #300	11/28	/17-12/7/17	
Dallas, TX 75204 214-253-5200		FEI NUM	BER	
Andrews to the British Theorem 1		30053	31940	
	ation: www.fda.gov/oc/industry DF INDIVIDUAL TO WHOM REPORT IS ISSUED			
FIRM NAME	J. Fontenot, Pharmacist-in-Charge	STREET ADDRESS		
W. SW. W. SER	rai vija			
Peoples Pharma	(TATO)	3801-B S. Lamar Blvd.		
Austin, TX 787		TYPE OF ESTABLISHMENT INSPECTED		
	I observed on 11/30/17 that the rubber sp	Producer of Non-Sterile Drug		
were discolored, cracked and damaged (unsmooth surface). There were several lots of different products made on the date including lot #11-30-2017@5 of Estradiol (E2)/Prog (P4) 0.5mg/100mg/GM Cream.				
	EMPLOYEE(S) SIGNATURE	EMPLOYEE(S) NAME AND TITLE (Print o	r Type) DATE ISSUED	
SEE REVERSE OF THIS	200			
OF THIS PAGE	Margaret M. anna	Margaret M. Annes, CSO	12/07/2017	